ScholarIQanswers from OpenAlex
Fondazione Lanza
InstitutionResearch output, impact & collaborations
Fondazione Lanza is a institution indexed in ScholarIQ from OpenAlex.
What is known about Fondazione Lanza?
ScholarIQrecord summary
Fondazione Lanza is a research organisation in Padova, IT. OpenAlex records 1,001 works and 52,092 citations for it. 233 researchers list it as their most recent affiliation.
How many works does Fondazione Lanza have?
ScholarIQindexed works
Fondazione Lanza has 1,001 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fondazione Lanza have?
ScholarIQcitation count
Fondazione Lanza has 52,092 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Fondazione Lanza?
ScholarIQresearcher count
Fondazione Lanza has 233 researchers in the ScholarIQ index.
What is the average h-index at Fondazione Lanza?
ScholarIQavg h-index
Fondazione Lanza has an average h-index of 65 in OpenAlex.
What is the ROR of Fondazione Lanza?
ScholarIQror
The ROR for Fondazione Lanza is on the source record.
What is the OpenAlex record for Fondazione Lanza?
ScholarIQopenalex
The OpenAlex for Fondazione Lanza is on the source record.
Who are the most-cited researchers behind Fondazione Lanza?
ScholarIQtop researchers by citations
What are the most-cited papers on Fondazione Lanza?
ScholarIQmost cited works
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
R. Charles Coombes, Emma Hall, Lorna J. Gibson, Robert Paridaens, Jacek Jassem, T. Delozier, Stephen E. Jones, Isabel Álvarez, Gianfilippo Bertelli, Olaf Ortmann, Alan S. Coates, Emilio Bajetta, David Dodwell, Robert E. Coleman, Lesley Fallowfield, E. Mickiewicz, Jørn Andersen, Per Eystein Lønning, Giorgio Cocconi, Alan L. Stewart, Nick Stuart, Claire Snowdon, M. Carpentieri, Giorgio Massimini, Judith M. Bliss
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Gianni Bonadonna, Ercole Brusamolino, Pinuccia Valagussa, Anna Rossi, Luisa Brugnatelli, Cristina Brambilla, Mario De Lena, Gabriele Tancini, Emilio Bajetta, R Musumeci, Umberto Veronesi
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Charles Coombes, Lucy Kilburn, CF Snowdon, Robert Paridaens, RE Coleman, SE Jones, Jacek Jassem, CJH van de Velde, T. Delozier, Isabel Álvarez, Lucia Del Mastro, Olaf Ortmann, K. Diedrich, AS Coates, Emilio Bajetta, Holmberg Sb, David Dodwell, E. Mickiewicz, J. Andersen, Per Eystein Lønning, Giorgio Cocconi, John Forbes, M. Castiglione, N Stuart, A. Stewart, Lesley Fallowfield, Gianfilippo Bertelli, Emma Hall, Richard Bogle, M. Carpentieri, E Colajori, Milayna Subar, Elizabeth Ireland, Judith M. Bliss
How much of the research on Fondazione Lanza is open access?
ScholarIQopen access share
50%OPEN ACCESS